U.S. markets closed

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
150.42-0.39 (-0.26%)
At close: 4:03PM EDT
150.25 -0.17 (-0.11%)
After hours: 05:17PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close150.81
Bid150.36 x 1000
Ask150.49 x 800
Day's Range149.92 - 151.54
52 Week Range130.05 - 180.36
Avg. Volume1,422,090
Market Cap31.414B
Beta (5Y Monthly)1.30
PE Ratio (TTM)34.26
EPS (TTM)4.39
Earnings DateNov 04, 2021
Forward Dividend & Yield0.96 (0.64%)
Ex-Dividend DateSep 29, 2021
1y Target Est185.54
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ZBH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zimmer Biomet Holdings, Inc.
    Analyst Report: Zimmer Biomet Holdings, Inc.Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Close to 60% of total revenue is derived from sales of large joints, another 22% comes from extremities and trauma; the remaining portion is primarily related to spine and dental products.
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Insider Monkey

    10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital

    In this article, we discuss 10 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital. If you want to skip our detailed analysis of Hawkins’ history, investment philosophy, and hedge fund performance, go directly to the 5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital. Lawrence Hawkins, the managing partner of Dallas-based […]

  • PR Newswire

    Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2021 Financial Results

    Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Thursday, November 4, 2021 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

  • Insider Monkey

    Should I Avoid Zimmer Biomet Holdings Inc (ZBH)?

    In this article you are going to find out whether hedge funds think Zimmer Biomet Holdings Inc (NYSE:ZBH) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]